McKesson Europe AG (CAKFY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
McKesson Europe AG (CAKFY) trades at $4.10 with AI Score 35/100 (Grade D). McKesson Europe AG is a prominent European healthcare logistics and retail pharmacy provider, operating extensive pharmaceutical distribution networks and a significant retail pharmacy footprint. Market cap: $5.37B, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for CAKFY: CAKFY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CAKFY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CAKFY: 1/1 perspectives are bearish.
How is this calculated? →McKesson Europe AG (CAKFY) Healthcare & Pipeline Overview
McKesson Europe AG is a prominent European healthcare logistics and retail pharmacy provider, operating extensive pharmaceutical distribution networks and a significant retail pharmacy footprint. The company serves approximately 40,000 pharmacies and hospitals, offering a wide range of medical products and services across multiple European countries.
What Is the Investment Thesis for CAKFY?
McKesson Europe AG (CAKFY) presents as a foundational player in the European pharmaceutical distribution and retail pharmacy sectors, underpinned by an established and extensive operational network. With a market capitalization of $5.37B, the company's core strength lies in its ability to efficiently connect pharmaceutical manufacturers with approximately 40,000 pharmacies and hospitals through 90 wholesale branches and 70 distribution centers across Europe. This robust infrastructure provides a degree of stability in a critical industry. The company's dual-segment approach, combining large-scale distribution with a significant retail pharmacy presence (2,000 company-owned and 8,000 partner pharmacies), diversifies its revenue streams and market reach. However, the company currently operates with a negative profit margin of -0.5%, despite a gross margin of 8.7%, indicating operational challenges or significant investment phases. Its low beta of 0.13 suggests relatively low volatility compared to the broader market. Key value drivers include the ongoing demand for pharmaceutical products and healthcare services across Europe, coupled with the potential for optimizing its logistics and expanding its digital and home care offerings. Investors should closely monitor the impact of evolving healthcare regulations and persistent pricing pressures within the European pharmaceutical market, which represent ongoing risks to performance.
Based on FMP financials and quantitative analysis
CAKFY Key Highlights
- Market capitalization of $5.37B, reflecting its substantial presence in the European healthcare market.
- Reported a negative profit margin of -0.5%, indicating current operational challenges or investment phases.
- Achieved a gross margin of 8.7%, demonstrating profitability at the product level.
- Manages an extensive European network, serving approximately 40,000 pharmacies and hospitals.
- Employs a significant workforce of 26,329 individuals, highlighting its operational scale.
Who Are CAKFY's Competitors?
CAKFY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HNGZY Hangzhou Tigermed Consulting Co., Ltd. | $4.45 | +0.00% | $6.86B | 45 |
| GALNF Galenica AG | $115.00 | +0.00% | $5.73B | 46 |
| DPHAY Dechra Pharmaceuticals PLC | $98.00 | +1.98% | $5.58B | 48 |
| ABCZF Abcam plc | $22.25 | +0.68% | $5.12B | 46 |
| ANHGY Mediclinic International plc | $5.49 | +0.00% | $4.05B | 44 |
| CWB State Street SPDR Bloomberg Convertible Securities ETF | $105.34 | +0.92% | $4.62B | 47 |
| KSTR KraneShares SSE STAR Market 50 Index ETF | $28.75 | +2.00% | $67.07M | 47 |
| DAUG FT Vest U.S. Equity Deep Buffer ETF - August | $46.97 | +0.26% | $363.40M | 47 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CAKFY's Key Strengths?
- Extensive and well-established pharmaceutical distribution network across Europe.
- Significant retail pharmacy presence with 2,000 company-owned and 8,000 partner pharmacies.
- Diversified service offerings including wholesale, retail, e-commerce, and home care.
- Backed by its parent company, McKesson Corporation, providing strategic and financial support.
What Are CAKFY's Weaknesses?
- Currently operating with a negative profit margin of -0.5%.
- Vulnerability to evolving healthcare regulations across multiple European countries.
- Exposure to pricing pressures inherent in the pharmaceutical industry.
- Reliance on a complex supply chain that can be susceptible to disruptions.
What Could Drive CAKFY Stock Higher?
- Continued expansion and optimization of its e-commerce solutions and home care services across Europe, leveraging digital trends.
- Strategic initiatives to strengthen and broaden pharmacy cooperation programs in existing and new European markets.
- Efforts to enhance efficiency and reduce costs within its extensive logistics and distribution network through technological upgrades.
- Potential for increased demand for pharmaceutical distribution services driven by an aging European population and evolving healthcare needs.
What Are the Key Risks for CAKFY?
- Negative return on equity (-2.3%) — the business is not currently generating profit on shareholder capital.
- Exposure to evolving and complex healthcare regulations across multiple European countries, which can impact operational models and profitability.
- Persistent pricing pressures within the highly competitive European pharmaceutical industry, potentially compressing profit margins.
- The negative profit margin of -0.5% could indicate underlying operational inefficiencies or significant investment phases that may impact long-term profitability if not addressed.
- Intense competition from other large pharmaceutical distributors and retail pharmacy chains in its key European markets.
What Are the Growth Opportunities for CAKFY?
- Expansion of E-commerce and Home Care Services: The growing trend towards digital health and patient convenience presents a significant opportunity. McKesson Europe AG, through its Lloyds Pharmacy brand, already offers e-commerce solutions and home care services, principally in Belgium, Ireland, Italy, and the United Kingdom. Expanding the geographical reach and scope of these digital platforms and home delivery services across its broader European network could tap into an increasing market demand for accessible healthcare. This leverages existing infrastructure and brand recognition to capture a larger share of the evolving digital pharmacy market, enhancing patient engagement and convenience.
- Deepening Pharmacy Cooperation Initiatives: McKesson Europe AG supports pharmacists by organizing and managing pharmacy cooperation initiatives in countries like Great Britain, France, Portugal, and Belgium. There is an opportunity to expand these programs to more regions and enhance the services offered, such as shared marketing, procurement advantages, and professional development. Strengthening these partnerships can create a more cohesive network of independent pharmacies, increasing their competitiveness against larger chains and fostering loyalty to McKesson Europe's distribution services, thereby securing long-term revenue streams and market influence.
- Optimization and Modernization of Logistics Infrastructure: With 70 distribution centers and 90 wholesale branches across Europe, McKesson Europe AG possesses a vast logistics network. Investing in advanced automation, data analytics, and supply chain technologies can significantly enhance efficiency, reduce operational costs, and improve delivery times. Such optimization would not only strengthen its competitive advantage in pharmaceutical distribution but also allow for handling higher volumes and more complex product lines, including temperature-sensitive biologics, thereby expanding its service capabilities and market share in a critical segment of the healthcare supply chain.
- Broadening the Product and Service Portfolio: Beyond traditional prescription drugs and OTC items, McKesson Europe AG's offerings extend to various medical services. There is an opportunity to strategically broaden this portfolio to include a wider range of high-margin medical devices, specialized healthcare products, or even value-added services for pharmacies, such as inventory management solutions or patient adherence programs. This diversification could tap into new revenue streams, reduce reliance on traditional drug distribution, and strengthen its position as a comprehensive partner for healthcare providers, catering to evolving patient and pharmacy needs across Europe.
- Leveraging Data Analytics for Market Insights: With its extensive network serving 40,000 pharmacies and hospitals and managing 70 distribution centers, McKesson Europe AG collects a vast amount of operational and market data. Developing sophisticated data analytics capabilities can provide invaluable insights into market trends, demand patterns, inventory optimization, and customer behavior. This insight can inform strategic decisions regarding product stocking, pricing, and service development, leading to more efficient operations, better-targeted offerings, and a stronger competitive edge in anticipating and responding to the dynamic needs of the European pharmaceutical and healthcare markets.
What Opportunities Does CAKFY Have?
- Expansion of e-commerce and home care services to meet growing digital demand.
- Deepening pharmacy cooperation initiatives to strengthen market presence and loyalty.
- Optimization of logistics infrastructure through technology for enhanced efficiency.
- Strategic broadening of product and service portfolio beyond traditional drugs.
What Threats Does CAKFY Face?
- Intensifying competition from other large pharmaceutical distributors and retail chains.
- Adverse changes in national healthcare policies and reimbursement models.
- Economic downturns impacting consumer spending on non-essential health items.
- Supply chain disruptions or increased costs for pharmaceutical products.
What Are CAKFY's Competitive Advantages?
- Extensive Distribution Network: A vast and established infrastructure of 90 wholesale branches and 70 distribution centers across Europe.
- Significant Retail Footprint: Operates 2,000 company-owned pharmacies and partners with 8,000 others, creating broad market access.
- Integrated Service Offering: Combines wholesale, retail, e-commerce, and home care services, providing a comprehensive solution.
- Brand Recognition: Leveraging the Lloyds Pharmacy brand in key markets enhances consumer trust and loyalty.
- Economies of Scale: Large-scale operations allow for efficient procurement and logistics, potentially lowering costs.
What Does CAKFY Do?
McKesson Europe AG, headquartered in Stuttgart, Germany, functions as a global provider of logistics and a diverse array of services tailored for the pharmaceutical and healthcare industries. The company's operational framework is bifurcated into two principal segments: Pharmaceutical Distribution and Retail Pharmacy. The Pharmaceutical Distribution division is dedicated to the wholesale supply of a broad spectrum of medicines and other health-related products. This segment boasts an extensive reach, serving approximately 40,000 pharmacies and hospitals through a network of 90 wholesale branches and managing 70 distribution centers strategically located across Europe. This robust infrastructure underscores its critical role in the European pharmaceutical supply chain. Concurrently, the Retail Pharmacy division oversees a significant footprint of approximately 2,000 company-owned pharmacies. Beyond its proprietary network, this segment also fosters collaborations with around 8,000 partner pharmacies through its established brand program, thereby extending its market penetration. Operating predominantly under the recognizable Lloyds Pharmacy brand, this division delivers a comprehensive suite of services including outpatient medication services, advanced e-commerce solutions, and essential home care services. These offerings are primarily concentrated in key European markets such as Belgium, Ireland, Italy, and the United Kingdom. McKesson Europe AG's product portfolio is expansive, encompassing traditional prescription drugs, a wide range of over-the-counter (OTC) items, and various medical services designed to support patient care. Furthermore, the company actively supports pharmacists by organizing and managing pharmacy cooperation initiatives in several European nations, including Great Britain, France, Portugal, and Belgium, aiming to enhance professional collaboration and service quality. The company's heritage is deeply rooted, tracing back to its establishment in 1835 under its former identity, Celesio AG, before undergoing a strategic rebranding to McKesson Europe AG in September 2017. It operates as a significant subsidiary of the larger McKesson Corporation, leveraging the resources and expertise of its parent entity.
What Products and Services Does CAKFY Offer?
- Wholesale distribution of medicines and health-related products to pharmacies and hospitals.
- Operate a network of approximately 2,000 company-owned retail pharmacies.
- Collaborate with around 8,000 partner pharmacies through brand programs.
- Provide outpatient medication services under the Lloyds Pharmacy brand.
- Offer e-commerce solutions for pharmaceutical products.
- Deliver home care services, primarily in Belgium, Ireland, Italy, and the UK.
- Supply traditional prescription drugs and over-the-counter (OTC) items.
- Organize and manage pharmacy cooperation initiatives in several European countries.
How Does CAKFY Make Money?
- Generates revenue through the wholesale distribution of pharmaceuticals and health products to healthcare providers.
- Earns income from direct sales of prescription and over-the-counter medications through its retail pharmacy network.
- Receives fees or shares profits from pharmacy cooperation programs and partnerships.
- Provides specialized services such as e-commerce and home care, contributing to service-based revenue.
What Industry Does CAKFY Operate In?
McKesson Europe AG operates within the dynamic and highly regulated European healthcare sector, specifically positioned in medical distribution and retail pharmacy. This industry is characterized by a critical role in ensuring the efficient and timely supply of medicines and health products from manufacturers to end-users, including pharmacies, hospitals, and directly to consumers. The competitive landscape includes other large-scale distributors and pharmacy chains, all navigating complex regulatory frameworks and national healthcare policies. Current market trends emphasize supply chain resilience, increasing demand for specialty pharmaceuticals, and the growing importance of digital health solutions and e-commerce in pharmacy services. McKesson Europe AG, with its extensive network of 90 wholesale branches and 70 distribution centers, alongside its 2,000 company-owned and 8,000 partner pharmacies, holds a significant position, acting as a crucial intermediary in this essential market. The company's focus on both wholesale and retail segments allows it to capture value across different points of the pharmaceutical value chain.
Who Are CAKFY's Key Customers?
- Pharmacies (approximately 40,000 served by distribution arm).
- Hospitals (served by distribution arm).
- Individual consumers (through company-owned and partner retail pharmacies).
- Independent pharmacists participating in cooperation initiatives.
Company Profile
McKesson Europe AG operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Stuttgart, DE. The company is led by CEO Tilo Köster. CAKFY has traded publicly since 2010.
How McKesson Europe AG Is Valued
McKesson Europe AG carries a market capitalization of $5.37B, placing it in the mid-cap category. Relative to its peer group, CAKFY's quantitative score of 35/100 is below the peer average of 46/100.
ROE -2%Key Financial Metrics
Return on equity for McKesson Europe AG stands at -2.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.4%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
McKesson Europe AG's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.13 places it in the safe zone, indicating low near-term bankruptcy risk.
CAKFY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider activity shows key executives buying shares, indicating confidence in the company's future performance.
- Community sentiment has shifted positively, with discussions highlighting McKesson's strong position in the healthcare supply chain.
- Analysts are optimistic about McKesson's innovative strategies in expanding its digital health services, attracting investor interest.
- The company's efforts in sustainability and corporate responsibility resonate well with socially conscious investors.
Bear Case
- Concerns over regulatory changes in the healthcare sector have raised doubts about McKesson's operational stability.
- Social media sentiment has seen a rise in skepticism regarding the company's ability to maintain its market share amidst increasing competition.
- Recent reports suggest challenges in supply chain logistics that could impact McKesson's efficiency and profitability.
- Some community members express worries about potential disruptions from geopolitical factors affecting European operations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CAKFY Latest News
No recent news available for CAKFY.
CAKFY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CAKFY.
Price Targets
Wall Street price target analysis for CAKFY.
CAKFY MoonshotScore
What does this score mean?
The MoonshotScore rates CAKFY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Tilo Köster
Managing Director
Tilo Köster's specific career history, educational background, and previous roles prior to his current position at McKesson Europe AG are not provided in the source data. His credentials and detailed professional journey remain unknown based on the available information.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Tilo Köster's leadership at McKesson Europe AG are not detailed in the provided source data. Information regarding the company's performance or strategic direction under his tenure is not available.
CAKFY OTC Market Information
McKesson Europe AG (CAKFY) trades on the OTC Other tier, which is the lowest of the three tiers for OTC Markets Group. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, which have stringent listing requirements regarding financial reporting, minimum share prices, and corporate governance, OTC Other companies have limited or no public disclosure requirements. This tier is for companies that do not meet the standards for OTCQX or OTCQB, or choose not to provide financial information to the public. Investors typically face higher risks due to less transparency compared to exchange-listed or even higher-tier OTC stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure and transparency, making comprehensive due diligence difficult.
- Lower liquidity and wider bid-ask spreads, potentially impacting trade execution and price.
- Increased volatility due to fewer market participants and less regulatory oversight.
- Higher susceptibility to fraud or manipulation given the less stringent reporting environment.
- Potential for delisting or further market tier downgrades if disclosure remains insufficient.
- Verify the company's operational existence and business activities independently.
- Assess the financial health and performance through any available reports, even if limited.
- Research the parent company, McKesson Corporation, for insights into overall stability.
- Investigate any news or regulatory filings from European authorities regarding the company.
- Understand the ownership structure and any significant insider holdings.
- Evaluate the company's competitive position within its specific European markets.
- Consult with a financial advisor experienced in OTC markets.
- Operates as a subsidiary of a major U.S. healthcare company, McKesson Corporation.
- Established in 1835, indicating a long operational history.
- Employs a significant workforce of 26,329 individuals.
- Maintains extensive physical assets, including 90 wholesale branches and 70 distribution centers.
- Manages a large network of 2,000 company-owned and 8,000 partner pharmacies.
CAKFY Healthcare Stock FAQ
What are McKesson Europe AG's primary business segments and their focus?
McKesson Europe AG operates through two core segments: Pharmaceutical Distribution and Retail Pharmacy. The Pharmaceutical Distribution segment is dedicated to the wholesale supply of medicines and health products, serving approximately 40,000 pharmacies and hospitals via a network of 90 wholesale branches and 70 distribution centers across Europe. The Retail Pharmacy segment manages about 2,000 company-owned pharmacies and collaborates with 8,000 partners, primarily under the Lloyds Pharmacy brand. This segment offers outpatient medication services, e-commerce, and home care in countries like Belgium, Ireland, Italy, and the United Kingdom, providing a comprehensive healthcare service offering.
How does McKesson Europe AG manage its extensive European distribution network?
McKesson Europe AG manages a vast and complex distribution network designed to efficiently deliver pharmaceuticals and health products across Europe. This network comprises 90 wholesale branches and 70 strategically located distribution centers, enabling it to reach approximately 40,000 pharmacies and hospitals. The company's operational model focuses on robust logistics to ensure timely and reliable supply. This infrastructure is critical for handling a diverse product portfolio, including traditional prescription drugs and over-the-counter items, and is a key component of its ability to serve a wide geographic area and maintain its market position as a leading healthcare logistics provider.
What are the key financial characteristics and risks associated with McKesson Europe AG?
McKesson Europe AG has a market capitalization of $5.37B. Financially, the company reported a gross margin of 8.7% but a negative profit margin of -0.5%, indicating that operational costs or other expenses are currently outweighing gross profits. Its beta of 0.13 suggests relatively low stock price volatility compared to the broader market. Key risks include ongoing exposure to evolving healthcare regulations across its diverse European operating regions, which can significantly impact its business model. Additionally, the company faces persistent pricing pressures within the highly competitive pharmaceutical industry, which can challenge profitability and growth prospects.
What are the key factors to evaluate for CAKFY?
McKesson Europe AG (CAKFY) holds an AI score of 35/100 (low). Not financial advice.
How frequently does CAKFY data refresh on this page?
CAKFY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CAKFY's recent stock price performance?
McKesson Europe AG (CAKFY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive and well-established pharmaceutical distribution network across Europe. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CAKFY overvalued or undervalued right now?
Valuing McKesson Europe AG (CAKFY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CAKFY?
Before investing in McKesson Europe AG (CAKFY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information regarding specific CEO background, education, and track record is not provided in the source data and thus marked as 'Unknown'.
- Specific market sizes and timelines for growth opportunities are inferred from the business description and general industry trends, not explicitly stated in the source data.
- The 'disclosureLevel' for OTC analysis is marked 'Unknown' as per the provided source data.